A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

NCT06516978 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

528

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Polatuzumab vedotin
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Orelabrutinib
DRUG: Venetoclax
DRUG: Chidamide
DRUG: Penpulimab
DRUG: Lenalidomide

Sponsor

The First Affiliated Hospital with Nanjing Medical University